Inspiro Medical

Nimrod Kaufmann of Inspiro

Inspiro CEO Nimrod Kaufmann presents the company’s smart dry powder inhaler during a Trendlines Medical U.S. Road Show event in New York.

The Need

Currently available inhalers, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, are often less than effective in delivering the necessary medication.

The optimal delivery device aims for the most efficient and effective deposition of aerosol medication, accounting for drug particle/droplet size and the patient’s ability to understand and use the device.

MDIs require hand-breath coordination. DPIs are breath actuated and may require forceful inhalation. Many patients do not use these devices properly because of the complexities. With nebulizers, treatment time is relatively long, setup is cumbersome, and the apparatus is usually bulky and inconvenient.

The market needs an innovative aerosol delivery device that is convenient and easy to use; delivers medication effectively; and suits adults, children, the elderly, and the seriously ill.

The Product

Inspiro Medical is developing Inspiromatic™, a breakthrough DPI that uses advanced technology to overcome the drawbacks of current inhalers. Inspiro’s proprietary DPI is the first device to combine an active dry powder fluidization mechanism that works at low inhalation flow rates with a unique real-time feedback control and data logger indicating proper inhalation technique and follow-up.

Inspiromatic assures optimal drug delivery. Young children and the elderly will particularly benefit from the advantages of Inspiro’s dry powder inhalation.

The Team

  • Nimrod Kaufmann, CEO: Extensive experience in the medical device industry, taking products from initial concept through manufacturing; B.Sc., mechanical engineering, Ben-Gurion University of the Negev
  • Guy Steuer, M.D., Inventor: Senior physician and pediatric pulmonologist, Schneider Children’s Medical Center of Israel; lecturer, Tel Aviv University; involved in development of numerous medical devices; consulted to Tree of Life Pharma and Stata Venture Partners, among others; M.D. and B.Sc., Hebrew University of Jerusalem; pulmonology fellowship, University of Pittsburgh

The Market

Inspiro’s smart DPI designed for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization, an estimated 300 million people worldwide suffer from asthma, with 250,000 deaths attributed to the disease annually. COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2020.

Inspiro Medical

Novel dry powder inhaler

At a Glance

Stage: Business development
Founded: 2010
Investor: The Trendlines Group
IP: National phase
Achievements: Q2 2013 completed FIM clinical trial; Q4 2013 pre-marketing device

In the Media

Inspiromatic™ featured in the media

Contact

Nimrod Kaufmann, CEO
Office: +972.72.260.7051
Mobile: +972.52.838.1919
nimrod@inspiromedical.com
www.inspiromedical.com